Georgia 2025-2026 Regular Session

Georgia House Bill HB1329

Introduced
2/17/26  
Report Pass
2/24/26  
Engrossed
2/25/26  
Refer
2/26/26  
Report Pass
3/18/26  
Enrolled
4/6/26  
Chaptered
5/5/26  

Caption

Controlled substances; Schedule I; provide certain provisions

Impact

The modifications proposed in HB 1329 can have significant implications on state laws concerning the regulation of pharmaceuticals and controlled substances. By revising classifications and updating definitions, the bill seeks to align state law with contemporary practices in drug safety and effectiveness. This could result in improved access to essential medications, as well as a more refined regulatory environment that may better distinguish between harmful and beneficial substances. Additionally, the bill sets the groundwork for future legislative actions regarding the evolving nature of drug therapies and treatments.

Summary

House Bill 1329 aims to amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, specifically addressing provisions related to Schedule I controlled substances and the definition of dangerous drugs. The bill proposes revisions that include changes to specifics regarding the categorization and regulations established for various drugs defined under Schedule I. Notably, it aims to update existing laws to reflect current scientific and medical understandings of controlled substances, with the intent to improve drug regulation within the state.

Sentiment

Overall, the sentiment towards HB 1329 appears to be supportive from many legislative members and healthcare advocates who argue for the necessity of modernizing the drug regulations in the face of new medical research and developments. The bill is viewed as a necessary step towards ensuring that Georgia's laws are in harmony with federal regulations and scientific advancements. However, there might be concerns from parties fearing that under-regulation could occur as a result of insufficient oversight in the categorization of drugs deemed dangerous.

Contention

Despite the supportive sentiment, there are likely points of contention regarding specific substances being classified under Schedule I, as well as the definition of dangerous drugs. Some stakeholders may argue that the bill could lead to misclassifications affecting patient access to vital medications or create loopholes that could be exploited. As the bill progresses, discussions will likely focus on ensuring that regulatory measures remain stringent enough to protect public health while also accommodating necessary medical advancements in drug therapy.

Companion Bills

No companion bills found.

Previously Filed As

GA HB473

Controlled substances; Schedule I; provide certain provisions

GA HB382

Controlled substances; Schedule I; psilocybin; revise a provision

GA HB968

Controlled substances; mitragynine and hydroxymitragynine (7-OH) are Schedule I; provide

GA HB458

Controlled substances; possession of four grams or more of fentanyl; provisions

GA SB558

Controlled Substances; possession of certain quantities of marijuana constitute a misdemeanor; provide

GA HB1089

Controlled substances; ivermectin as an over-the-counter medication; provide

GA SB6

Controlled Substances; determine whether a controlled substance has been adulterated; authorize the use of testing equipment

GA SB132

Controlled substances; psychoactive derivatives of hemp added as Schedule I drug

GA HB1469

Crimes; restriction and seal of certain records upon sentencing of a first conditional discharge for possession of controlled substances and certain nonviolent property crimes; provide

GA SB366

Controlled Substances and Pharmacists and Pharmacies; ivermectin as an over-the-counter medication in this state; provide

Similar Bills

No similar bills found.